Current status of clinical researches on metastatic triple negative breast cancer

doi:10.3760/cma.j.issn.1673-422X.2020.03.008

Abstract

Abstract:

Triple negative breast cancer (TNBC) is associated with a high risk of recurrence and generally a poor prognosis. Median survival time of metastatic triple negative breast cancer (mTNBC) is about one year. Currently, the mainstay of treatment for mTNBC remains cytotoxic chemotherapy. In recent years, the drugs involved in the clinical researches of mTNBC include poly-ADP-ribose polymerase inhibitors, phosphoinositide 3-kinase pathway inhibitors, antibody targeting epidermal growth factor receptor, antibody targeting trophoblast surface antigen-2, antibody targeting death receptor 5, endocrine therapy drugs for androgen receptor, and immune checkpoint inhibitors and so on. New drugs have gradually improved the survival of patients with mTNBC.

Key words: Triple negative breast neoplasms, Neoplasm metastasis, Clinical trial, Review

Li Kaichun, Wang Yajie. Current status of clinical researches on metastatic triple negative breast cancer[J]. Journal of International Oncology, 2020, 47(3): 169-173.

References 34

[1]	Waks AG, Winer EP . Breast cancer treatment: a review[J]. JAMA, 2019,321(3):288-300. DOI: 10.1001/jama.2018.19323. doi: 10.1001/jama.2018.19323
[2]	Isakoff SJ, Mayer EL, He L , et al. TBCRC 009: a multicenter phase Ⅱ clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015,33(17):1902-1909. DOI: 10.1200/JCO.2014.57.6660. doi: 10.1200/JCO.2014.57.6660
[3]	Tutt A, Tovey H, Cheang MCU , et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial[J]. Nat Med, 2018,24(5):628-637. DOI: 10.1038/s41591-018-0009-7. doi: 10.1038/s41591-018-0009-7
[4]	Yardley DA, Coleman R, Conte P , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial[J]. Ann Oncol, 2018,29(8):1763-1770. DOI: 10.1093/annonc/mdy201. doi: 10.1093/annonc/mdy201
[5]	Zhang J, Wang Z, Hu X , et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer[J]. Int J Cancer, 2015,136(1):204-211. DOI: 10.1002/ijc.28966. doi: 10.1002/ijc.v136.1
[6]	Hu XC, Zhang J, Xu BH , et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015,16(4):436-446. DOI: 10.1016/S1470-2045(15)70064-1. doi: 10.1016/S1470-2045(15)70064-1
[7]	Zhang J, Wang L, Wang Z , et al. A phase Ⅱ trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer[J]. Cancer Biol Ther, 2015,16(2):225-232. DOI: 10.4161/15384047.2014.986973. doi: 10.4161/15384047.2014.986973
[8]	Li Q, Li Q, Zhang P , et al. A phase Ⅱ study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes[J]. Cancer Biol Ther, 2015,16(12):1746-1753. DOI: 10.1080/15384047.2015.1095400. doi: 10.1080/15384047.2015.1095400
[9]	Robson M, Im SA, Senkus E , et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017,377(6):523-533. DOI: 10.1056/NEJMoa1706450. doi: 10.1056/NEJMoa1706450
[10]	Robson ME, Tung N, Conte P , et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol, 2019,30(4):558-566. DOI: 10.1093/annonc/mdz012. doi: 10.1093/annonc/mdz012
[11]	Litton JK, Rugo HS, Ettl J , et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018,379(8):753-763. DOI: 10.1056/NEJ Moa1802905. doi: 10.1056/NEJMoa1802905
[12]	Turner NC, Telli ML, Rugo HS , et al. A phase Ⅱ study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)[J]. Clin Cancer Res, 2019,25(9):2717-2724. DOI: 10.1158/1078-0432.CCR-18-1891. doi: 10.1158/1078-0432.CCR-18-1891
[13]	Vinayak S, Tolaney SM, Schwartzberg L , et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. JAMA Oncol, 2019,Inpress. DOI: 10.1001/jamaoncol.2019.1029.
[14]	Rodler ET, Kurland BF, Griffin M , et al. Phase Ⅰ study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer[J]. Clin Cancer Res, 2016,22(12):2855-2864. DOI: 10.1158/1078-0432.CCR-15-2137. doi: 10.1158/1078-0432.CCR-15-2137
[15]	Somlo G, Frankel PH, Arun BK , et al. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083[J]. Clin Cancer Res, 2017,23(15):4066-4076. DOI: 10.1158/1078-0432.CCR-16-2714. doi: 10.1158/1078-0432.CCR-16-2714
[16]	Han HS, Diéras V, Robson M , et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase Ⅱ study[J]. Ann Oncol, 2018,29(1):154-161. DOI: 10.1093/annonc/mdx505. doi: 10.1093/annonc/mdx505
[17]	Pascual J, Turner NC . Targeting the PI3-kinase pathway in triple negative breast cancer[J]. Ann Oncol, 2019,30(7):1051-1060. DOI: 10.1093/annonc/mdz133. doi: 10.1093/annonc/mdz133
[18]	Kim SB, Dent R, Im SA , et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2017,18(10):1360-1372. DOI: 10.1016/S1470-2045(17)30450-3. doi: 10.1016/S1470-2045(17)30450-3
[19]	Carey LA, Rugo HS, Marcom PK , et al. TBCRC 001: randomized phase Ⅱ study of cetuximab in combination with carboplatin in stage Ⅳ triple-negative breast cancer[J]. J Clin Oncol, 2012,30(21):2615-2623. DOI: 10.1200/JCO.2010.34.5579. doi: 10.1200/JCO.2010.34.5579
[20]	Baselga J, Gómez P, Greil R , et al. Randomized phase Ⅱ study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer[J]. J Clin Oncol, 2013,31(20):2586-2592. DOI: 10.1200/JCO.2012.46.2408. doi: 10.1200/JCO.2012.46.2408
[21]	Bardia A, Mayer IA, Diamond JR , et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer[J]. J Clin Oncol, 2017,35(19):2141-2148. DOI: 10.1200/JCO.2016.70.8297. doi: 10.1200/JCO.2016.70.8297
[22]	Bardia A, Mayer IA, Vahdat LT , et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019,380(8):741-751. DOI: 10.1056/NEJMoa1814213. doi: 10.1056/NEJMoa1814213
[23]	Forero-Torres A, Varley KE, Abramson VG , et al. TBCRC 019: a phase Ⅱ trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer[J]. Clin Cancer Res, 2015,21(12):2722-2729. DOI: 10.1158/1078-0432.CCR-14-2780. doi: 10.1158/1078-0432.CCR-14-2780
[24]	Bonnefoi H, Grellety T, Tredan O , et al. A phase Ⅱ trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)[J]. Ann Oncol, 2016,27(5):812-818. DOI: 10.1093/annonc/mdw067. doi: 10.1093/annonc/mdw067
[25]	Traina TA, Miller K, Yardley DA , et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer[J]. J Clin Oncol, 2018,36(9):884-890. DOI: 10.1200/JCO.2016.71.3495. doi: 10.1200/JCO.2016.71.3495
[26]	Nanda R, Chow LQ, Dees EC , et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ⅰb KEYNOTE-012 study[J]. J Clin Oncol, 2016,34(21):2460-2467. DOI: 10.1200/JCO.2015.64.8931. doi: 10.1200/JCO.2015.64.8931
[27]	Adams S, Schmid P, Rugo HS , et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019,30(3):397-404. DOI: 10.1093/annonc/mdy517. doi: 10.1093/annonc/mdy517
[28]	Adams S, Loi S, Toppmeyer D , et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019,30(3):405-411. DOI: 10.1093/annonc/mdy518. doi: 10.1093/annonc/mdy518
[29]	Voorwerk L, Slagter M, Horlings HM , et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med, 2019,25(6):920-928. DOI: 10.1038/s41591-019-0432-4. doi: 10.1038/s41591-019-0432-4
[30]	Emens LA, Cruz C, Eder JP , et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study[J]. JAMA Oncol, 2019,5(1):74-82. DOI: 10.1001/jamaoncol.2018.4224. doi: 10.1001/jamaoncol.2018.4224
[31]	Adams S, Diamond JR, Hamilton E , et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial[J]. JAMA Oncol, 2019,5(3):334-342. DOI: 10.1001/jamaoncol.2018.5152. doi: 10.1001/jamaoncol.2018.5152
[32]	Schmid P, Adams S, Rugo HS , et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018,379(22):2108-2121. DOI: 10.1056/NEJ Moa1809615. doi: 10.1056/NEJMoa1809615
[33]	D'Abreo N, Adams S . Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?[J]. Nat Rev Clin Oncol, 2019,16(7):399-400. DOI: 10.1038/s41571-019-0216-2. doi: 10.1038/s41571-019-0216-2
[34]	Brahmer JR, Lacchetti C, Schneider BJ , et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018,36(17):1714-1768. DOI: 10.1200/JCO.2017.77.6385. doi: 10.1200/JCO.2017.77.6385